On April 21, 2026, VectorBuilder announced a significant scientific breakthrough led by its Chief Scientist, Dr. Bruce Lahn, that sheds light on one of biology’s most enduring questions: how a single fertilized egg gives rise to the vast array of specialized cell types in the human body.
The research team introduced a novel technique called Potency-Seq, designed to measure a gene’s transcriptional potency — essentially determining whether a silent gene retains the potential to be activated or has permanently lost that ability. Through this method, the scientists observed that as stem cells differentiate into specific cell types such as neurons, muscle, or blood cells, their genome progressively loses transcriptional potency.
More genes become permanently blocked, or “occluded,” from responding to transcription factors, even when those factors are present in the cell. Dr. Lahn’s team termed this progressive and irreversible process “occlusis,” describing it as a fundamental mechanism that gradually restricts the developmental potential of differentiating cells.
The findings suggest that the core definition of a cell type may not lie solely in its current gene expression pattern, but rather in which genes across the genome remain transcriptionally potent versus those that have become occluded. This reframing could influence how scientists understand cell identity and developmental biology at a foundational level.
VectorBuilder highlighted that the nature of this discovery is foundational, with implications that could one day contribute to advancements in regenerative medicine, disease modeling, and stem cell research. The company noted that the function’s significance has been recognized as having Nobel Prize potential.
The announcement was made via Globe NewsWire from VectorBuilder’s headquarters in Chicago, Illinois, on April 21, 2026, and was distributed as a paid press release.
